Biolex Therapeutics Announces Initiation Of Locteron(TM) Phase 2 Clinical Study In Chronic Hepatitis C

Wed, 31 Jan 2007 02:00 PM EST

... Biolex Therapeutics today announced the initiation of a Phase 2a clinical trial of its lead product candidate Locteron(TM), a best-in-class controlled-release interferon alfa. Locteron is being developed as a treatment for chronic hepatitis C, a virus infecting more than four million people in the United States. [click link for full article] ...